ReviewFrontiers in genetics2019
Single-Cell Analysis of Circulating Tumor Cells: How Far Have We Come in the -Omics Era?
Review in Frontiers in genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 66 citations in OpenAlex.
- Optimizing Detection of Circulating Tumor Cells in Breast Cancer: Unveiling New Markers for Clinical Applications.International journal of molecular sciences · 2025Article
- Clinical significance of genomic sequencing of circulating tumour cells (CTCs) in cancer.The journal of liquid biopsy · 2024Review
- Feasibility of mass cytometry proteomic characterisation of circulating tumour cells in head and neck squamous cell carcinoma for deep phenotyping.British journal of cancer · 2023Article
- Integrated "lab-on-a-chip" microfluidic systems for isolation, enrichment, and analysis of cancer biomarkers.Lab on a chip · 2023Review
- Single-Cell Analysis in theGenes · 2023Review
- Sequence-Based Platforms for Discovering Biomarkers in Liquid Biopsy of Non-Small-Cell Lung Cancer.Cancers · 2023Review
- Recent Advances of Microfluidic Platform for Cell Based Non-Invasive Prenatal Diagnosis.International journal of molecular sciences · 2023Review
- Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA.Therapeutic advances in medical oncology · 2023Review
- Development and clinical validation of a microfluidic-based platform for CTC enrichment and downstream molecular analysis.Frontiers in oncology · 2023Article
- Accurate isolation and detection of circulating tumor cells using enrichment-free multiparametric high resolution imaging.Frontiers in oncology · 2023Article
- Deep transfer learning enables lesion tracing of circulating tumor cells.Nature communications · 2022Article
- Isolation of TTF-1 Positive Circulating Tumor Cells for Single-Cell Sequencing by Using an Automatic Platform Based on Microfluidic Devices.International journal of molecular sciences · 2022Article
- Characterizing the epithelial-mesenchymal transition status of circulating tumor cells in head and neck squamous cell carcinoma.Head & neck · 2022Article
- Genome-wide in vivo screen of circulating tumor cells identifiesScience advances · 2022Article
- A pipeline for copy number profiling of single circulating tumour cells to assess intrapatient tumour heterogeneity.Molecular oncology · 2022Article
- Size-based isolation and detection of renal carcinoma cells from whole blood.Molecular and clinical oncology · 2022Article
- Unraveling Cancer Metastatic Cascade Using Microfluidics-based Technologies.Biophysical reviews · 2022Review
- Single-Cell RNA Sequencing Uncovers Heterogeneous Circulating Tumor Cell Subsets in Breast Cancer.Cancers · 2022Article
- Recent Developments of Circulating Tumor Cell Analysis for Monitoring Cutaneous Melanoma Patients.Cancers · 2022Review
- Correlation between targeted RNAseq signature of breast cancer CTCs and onset of bone-only metastases.British journal of cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor cells detach from the primary tumor or metastatic sites and enter the peripheral blood, often causing metastasis. These cells, named Circulating Tumor Cells (CTCs), display the same spatial and temporal heterogeneity as the primary tumor. Since CTCs are involved in tumor progression, they represent a privileged window to disclose mechanisms of metastases, while -omic analyses at the single-cell level allow dissection of the complex relationships between the tumor subpopulations and the surrounding normal tissue. However, in addition to reporting the proof of concept that we can query CTCs to reveal tumor evolution throughout the continuum of treatment for early detection of resistance to therapy, the scientific literature has also been highlighting the disadvantages of CTCs, which hampers a routine use of this approach in clinical practice. To date, an increasing number of CTC technologies, as well as -omics methods, have been employed, mostly lacking strong comparative analyses. The rarity of CTCs also represents a major challenge, because there is no consensus regarding the minimal criteria necessary and sufficient to define an event as CTC; moreover, we cannot often compare data from of one study with that of another. Finally, the availability of an individual tumor profile undermines the traditional histology-based treatment. Applying molecular data for patient benefit implies a collective effort by biologists, bioengineers, and clinicians, to create tools to interpret molecular data and manage precision medicine in every single patient. Herein, we focus on the most recent findings in CTC -omics to learn how far we have come.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.